芪苈强心胶囊对慢性心力衰竭患者炎症细胞因子的影响

目的探讨芪苈强心胶囊对慢性心力衰竭患者白细胞介素-1(IL-1)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)及高敏C反应蛋白(hs-CRP)的影响。方法 124例慢性心力衰竭患者随机分为芪苈强心胶囊治疗组及对照组,每组各62例,两组间临床基线资料无显著差异。芪苈强心胶囊治疗组在常规治疗基础上加用芪苈强心胶囊,每天3次,每次4粒。8周后观察两组患者的临床症状、心功能的改善情况。检测入组时及治疗8周后两组患者血浆BNP、IL-1、IL-6、TNF-α及hs-CRP的变化。结果芪苈强心胶囊治疗组临床显效率显著高于对照组(72.6%vs 53.2%,,P=0.040)。心脏彩超提示,芪苈强心治疗组左室射血分数(LVEF)较前有显著提高(36.5±3.4 vs41.4±2.9%,P0.05)。和对照组治疗后比较,芪苈强心治疗组LVEF也显著提高,有统计学差异(P0.05)。芪苈强心治疗组BNP、IL-1、IL-6、TNF-α和hs-CRP较入组时有显著降低(P值均0.05),和对照组治疗后比较也有显著性差异(P值均0.05)。结论慢性心力衰竭患者常规治疗基础上加用芪苈强心胶囊可进一步缓解临床症状、改善心功能、降低BNP及IL-1、IL-6、TNF-α等炎症因子的水平。

Effects of Qili Qiangxin capsules on inflammatory cytokine levels in patients with chronic heart failure

Objective To investigate the effects of Qili Qiangxin capsules on the levels of interleukin-1 （IL-1）, interleukin-6 （IL-6）, tumor necrosis factor-α （TNF-α）, and high-sensitivity C-reactive protein （hs-CRP） in patients with chronic heart failure （CHF）. Methods A total of 124 CHF patients were randomly and equally divided into treatment group （treated with Qili Qiangxin capsules） and control group. The baseline characteristics were comparable between the two groups. The treatment group received Qili Qiangxin capsules three times （4 capsules each time） daily in addition to routine treatment. After 8 weeks of treatment, the improvements in clinical symptoms and cardiac function were evaluated, and the changes in plasma brain natriuretic peptide （BNP）, IL-1, IL-6, TNF-α, and hs-CRP levels were assessed. Results The treatment group had a significantly higher marked response rate than the control group （72.6% vs 53.2%, P=0.040）. The echocardiography showed that the left ventricular ejection fraction of treatment group improved significantly after treatment （36.5±3.4 vs 41.4±2.9%, P〈0.05）, and it was significantly better in the treatment group than in the control group after treatment （P〈0.05）. In addition, the plasma BNP, IL-1, IL-6, TNF-α, and hs-CRP levels of treatment group were significantly reduced after treatment （P〈0.05 for all）, and they were significantly lower in the treatment group than in the control group after treatment （P〈0.05 for all）. Conclusion The use of Qili Qiangxin capsules in addition to routine treatment may further relieve clinical symptoms, improve cardiac function, and reduce plasma BNP, IL-1, IL-6, TNF-α, and hs-CRP levels in CHF patients.